Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France
Maxime Dougados,
Pascal Claudepierre,
Adeline Ruyssen-Witrand,
Philippe Goupille,
Alain Saraux,
Anne Tournadre,
Daniel Wendling,
Cédric Lukas,
Julien Lucas,
Emilie Desfleurs
Affiliations
Maxime Dougados
INSERM U1153, Paris, France
Pascal Claudepierre
Rheumatology, Henri Mondor Hospital Rheumatology Service, Creteil, France
Adeline Ruyssen-Witrand
Rheumatology, University Hospital Centre Toulouse, Toulouse, France
Philippe Goupille
Department of Rheumatology, CHRU de Tours, Tours, France
Alain Saraux
16 Rheumatology, CHU Brest, Brest, France
Anne Tournadre
1 Rheumatology, CHU Clermont-Ferrand, Clermont-Ferrand, France
Daniel Wendling
Department of Rheumatology, University Teaching Hospital, CHRU de Besançon, Besancon, France
Cédric Lukas
2 Department of Rheumatology, University Hospital Centre Montpellier, Montpellier, Languedoc-Roussillon, France
Julien Lucas
Biostatistics, RCTs, Lyon, France
Emilie Desfleurs
Medical affairs, Novartis Pharma SAS, Rueil-Malmaison, France
